3D Bioprinting Market to Reach Valuation of USD 1.8 Billion by 2028

In terms of revenue, the 3D Bioprinting Market is expected to reach USD 3.7 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 20.10% from 2022 to 2028. The growth of the 3D Bioprinting Market is driven by various technological advancements in 3D biomaterials and bioprinters, rising usage of 3D bioprinting in cosmetology and pharmaceutical industries and private as well as public funding are supporting bioprinting research activities.

Key Findings:

• The clinical sub-segment in applications segment is further categorized into skin printing, blood vessel printing, bone & cartilage printing, and others. In all these, skin printing is projected to grow during the forecast period. The growth is due to the technological advancements & new product launches coupled with an increasing number of aesthetic and reconstruction surgeries worldwide.
• The living cells segment is expected to cover the largest market mainly due to heavy R&D in fields of regenerative medicine coupled with rising investments for supporting the research.
• Asia Pacific is projected to have the fastest market growth. The factors driving the market growth is several advancements in tissue engineering that are being aimed at regeneration of damaged tissues as well as organs with the assistance of 3D bioprinting.

Some of the key players in the 3D Bioprinting Market include - Envisiontec Inc., Organovo Holdings Inc., Inventia Life Science PTY LTD, Poietis, Vivax Bio LLC, Allevi, Cyfuse Biomedical K.K., 3D Bioprinting Solutions, Cellink Global, Regemat 3D S.L..

Higher adoption of 3D bioprinting technology in the healthcare domain coupled with the fact that bioprinting has emerged as a promising technology for the fabrication of artificial tissues & organs can bring revolution in the diagnosis and treatment of several medical conditions. Additionally, bioprinting players all over the globe is continuously innovating in tissue engineering, regenerative medicine, drug therapies, and stem cell therapy, which is gaining importance among pharmaceutical companies and healthcare professionals to make the future better for patient care.

The Asia Pacific witnessing a higher market growth because of increasing research activities, high demand for organ transplants, and initiatives by market players for making their significant presence in different countries. China and India are countries projected to offer growth opportunities for major players driven by support from the government bodies, high demand for cosmetic surgeries.

Recent Developments:

December 2021: 3D bioprinting firm BICO has announced an initial $1.5 million contract manufacturing deal with degenerative joint replacement start-up Nanochon. The deal will see Nanochon purchase products and services worth $1.5 million from BICO’s SCIENION Company to develop its 3D printed regenerative joint implants, which the start-up claims will deliver faster recoveries for patients while reducing costs to health providers.